Trial Profile
Phase I study of monoclonal antibody anti-anb3 integrin in patients with advanced solid tumors
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Etaracizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 20 Dec 2006 Status change
- 24 Aug 2005 New trial record.